Balanced news tone
News Sentiment
6996 sentiment intelligence
Antengene Corporation Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-1.2% over one week, +19.6% over four weeks, trend inactive, and materially above fair value.
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 04:16
- Source
- The Manila Times
Antengene Corporation Limited commences an Equity Buyback Plan for 67,924,413 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2026.
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 09 Jul 2026 12:15
- Source
- marketscreener.com
K2 nabs two Antengene bispecific TCEs in $2B license, option deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 22 Jun 2026 07:00
- Source
- BioWorld News
Antengene licenses ATG-106 to K2 Therapeutics for $20M upfront
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 00:42
- Source
- Investing.com Nigeria
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jun 2026 07:00
- Source
- BioSpace
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 10 Jun 2026 07:00
- Source
- The Manila Times
Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 08 Jun 2026 07:00
- Source
- The Manila Times
UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 04 Mar 2026 08:00
- Source
- BioWorld News
UCB boards T cell engager train in $60M upfront deal with Antengene
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 04 Mar 2026 08:00
- Source
- Endpoints News
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2025 07:00
- Source
- BioSpace
Antengene Announces XPOVIO? (selinexor) Approved for Commercialization in Malaysia
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Aug 2024 07:00
- Source
- aap.com.au
Antengene
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2024 16:53
- Source
- The Pharma Letter
ANTENGENE CORPORATION LTD. - B (6996)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Nov 2020 08:00
- Source
- hkex.com.hk